Regen BioPharma
4700 Spring Street
Suite 304
La Mesa
California
91942
United States
Tel: 619-702-1404
Fax: 619-330-2328
Website: http://www.regenbiopharma.com/
168 articles about Regen BioPharma
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024
3/5/2024
Regen BioPharma, Inc. will be presenting at the Emerging Growth Conference on March 7, 2024.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024
2/5/2024
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on February 7, 2024 (https://emerginggrowth.com/conference/).
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024
1/8/2024
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on January 10, 2024 (https://emerginggrowth.com/conference/).
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 7, 2023
12/5/2023
Regen BioPharma, Inc. will be presenting at the Emerging Growth Conference on December 7, 2023.
-
Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments
11/16/2023
Regen BioPharma, Inc. announced that after interviewing several candidates it has selected a Contract Research Organization (CRO) to perform the next set of experiments to elucidate the effectiveness of the Company's DuraCAR cells.
-
Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program
11/14/2023
Regen BioPharma, Inc. has previously discussed initiation of its DuraCAR CAR T-cell therapeutic. This program is designed to create chimeric antigen T-cells that silence the gene for NR2F6.
-
Regen BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023
10/30/2023
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on November 1, 2023.
-
Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program
10/25/2023
Regen BioPharma, Inc. has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic.
-
Regen BioPharma, Inc. Expects Second Phase of Confirmatory Study Shortly
10/18/2023
Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) is currently developing a genetic approach to regulating NR2F6 levels in human T cells.
-
Regen BioPharma, Inc. Receives First Phase of Confirmatory Study
10/10/2023
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on October 5, 2023
10/3/2023
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on October 5 2023 (https://emerginggrowth.com/conference/).
-
Studies On Regen BioPharma, Inc.'s DURACAR Indicate Potential Suppression Of Autoimmunity, Company Retains Contract Research Organization To Conduct Additional Confirmatory Studies
9/19/2023
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) had previously discussed initiation of a series of experiments to validate its DuraCAR CAR-T cell therapeutic.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 6, 2023
9/6/2023
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) will be presenting at the Emerging Growth Conference on September 6, 2023 (https://emerginggrowth.com/conference/).
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023
8/8/2023
Regen BioPharma, Inc., a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on August 10, 2023.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on March 3, 2023
3/7/2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time interactive presentation at the Emerging Growth Conference.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 22, 2023
2/21/2023
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) (a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs) will be presenting at the Emerging Growth Conference on February 22, 2023.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 8, 2023
2/7/2023
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on February 8, 2023.
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023
1/23/2023
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs, will be presenting at the Emerging Growth Conference on January 25, 2023.
-
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio
1/20/2023
Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today the filing of a provisional patent application covering the use of survivin-engineered dendritic cells and exosomes for stimulation of anti-cancer immunity.
-
Regen BioPharma, Inc. to address 2023 goals and company direction at the Emerging Growth Conference on January 11, 2023
1/9/2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.